CardioInsight1: CardioInsight 1 RBBB

Sponsor
Chinese University of Hong Kong (Other)
Overall Status
Recruiting
CT.gov ID
NCT05555966
Collaborator
(none)
93
1
1
88
1.1

Study Details

Study Description

Brief Summary

Cardiac resynchronization therapy (CRT) is an established therapy for symptomatic heart failure patients. However, there are still 30 to 40% of studied patients being nonresponder to CRT. The plausible reasons of lack of effect of CRT in these patients include relative less baseline electrical dyssynchrony. The aim of our study is to investigate whether there is an optimal configuration of CRT delivery that varies between patients with different pattern of activation delay.

Condition or Disease Intervention/Treatment Phase
  • Device: Electrical Activation Mapping Guided Cardiac resynchronization therapy
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
93 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Electrical Activation Mapping Guided Tailor Made Approach for Cardiac Resynchronization Therapy
Actual Study Start Date :
Sep 1, 2017
Anticipated Primary Completion Date :
Aug 31, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Tailor-made CRT delivery

Device placement based on Electrical Activation Mapping result

Device: Electrical Activation Mapping Guided Cardiac resynchronization therapy
To study the feasibility to optimize configuration of CRT delivery for acute correction of electrical dyssynchrony using a noninvasive mapping of global electrical activation

Outcome Measures

Primary Outcome Measures

  1. Left Ventricle (LV) end systolic volume reduction [6 months]

    The responder rate of greater than 10% of LV end systolic volume reduction measured by echocardiogram

Secondary Outcome Measures

  1. Electrical dyssynchrony index [During procedure]

    The acute electrical dyssynchrony indices (the standard deviation of activation times throughout the epicardium) of different methods of CRT delivery. Lower indicate larger improvement.

  2. Hemodynamic response monitoring [During procedure]

    monitor the difference in hemodynamic responses of different methods of CRT delivery method. The hemodynamic response will be maximal dp/dt as measured by pressure wire introduced into the left ventricle during the procedure.

  3. Procedure outcome with optimal CRT delivery [During procedure]

    Procedure outcome measured by procedure duration and implantation success rate of the optimal CRT delivery method as determined by the best improvement in electrical dyssynchrony indices.

  4. Cine images and chest X ray [6 months]

    Cine images (PA, LAO 300, RAO 300) and Chest X ray (PA view) of patients will be obtained for evaluation of changes in disease

  5. Echocardiogram parameter: left ventricular systolic and diastolic volume [6 months]

    left ventricular systolic and diastolic volume at baseline, 3 months and 6 months : , left ventricular ejection fraction, degree of mitral regurgitation, strain imaging will be aggregated to arrive at an overall change in echocardiogram parameters as together they represent integrated heart function collectively, as reflected by the listed echocardiogram parameters.

  6. Multi-dimensional Quality of life changes [6 months]

    change in New York Heart Association (NYHA) class, 6 minute hall walk test, HF Patient Global Assessment Questionnaire and quality of life using Minnesota's living with heart failure (MLWHF) questionnaire at baseline, 3 months and 6 months.

  7. Device set-up parameter :defibrillation threshold [6 months]

    Device parameters including defibrillation threshold at implant and 6 months follow-up.

  8. Post-operation Complication rate [6 months]

    Peri-operative and 6 months follow-up complications rate: Thromboembolic event Dislodgement and migration of pacing leads Phrenic nerve stimulation Others

  9. Device set-up parameter :defibrillation sensitivity [6 months]

    Device set-up parameter :defibrillation sensitivity at implant and 6 months follow-up

  10. Device set-up parameter: lead impedance of pacing leads [6 months]

    Device set-up parameter: lead impedance of pacing leads at implant and 6 months follow-up

  11. Change in 6 minute hall walk test [6 months]

    Change in 6 minute hall walk test result, at baseline, 3 months and 6 months.

  12. Change in HF Patient Global Assessment Questionnaire [6 months]

    HF Patient Global Assessment Questionnaire at baseline, 3 months and 6 months.

  13. Change in quality of life [6 months]

    Change in quality of life assessed by Minnesota's living with heart failure (MLWHF) questionnaire at baseline, 3 months and 6 months.

  14. Implantation success rate with optimal CRT delivery [During procedure]

    Implantation success rate of the optimal CRT delivery method as determined by the best improvement in electrical dyssynchrony indices.

  15. Echocardiogram parameter: left ventricular ejection fraction [6 months]

    Echocardiogram parameter: left ventricular ejection fraction at baseline, 3 months and 6 months

  16. Echocardiogram parameter: degree of mitral regurgitation [6 months]

    Echocardiogram parameter: degree of mitral regurgitation at baseline, 3 months and 6 months

  17. Echocardiogram parameter: strain imaging [6 months]

    Echocardiogram parameter: strain imaging at baseline, 3 months and 6 months

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult (aged 18 or above) of both sexes

  • Ischemic or non-ischemic cause of heart failure

  • QRS duration > 120 ms, non-left bundle branch block (LBBB) type of conduction disturbance

  • NYHA class III or above

  • Informed consent by the patient

  • Already received stable dose of guideline directed medical therapy for at least 3 months

Exclusion Criteria:
  • LBBB patients

  • Pregnant women

  • Participation in another study

  • Patient with contraindication to left ventricle catheterization by a retrograde aortic approach

Contacts and Locations

Locations

Site City State Country Postal Code
1 The Chinese University of Hong Kong Shatin Hong Kong 999077

Sponsors and Collaborators

  • Chinese University of Hong Kong

Investigators

  • Principal Investigator: Bryan Yan, Chinese University of Hong Kong

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Professor Bryan Ping Yen YAN, Professor, Chinese University of Hong Kong
ClinicalTrials.gov Identifier:
NCT05555966
Other Study ID Numbers:
  • 2017.316
First Posted:
Sep 27, 2022
Last Update Posted:
Sep 27, 2022
Last Verified:
Sep 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 27, 2022